For the Media
Dr. Rainer Storb is a member of Fred Hutch's Clinical Research Division and head of the Program in Transplantation Biology. His research is directed at understanding and eliminating major barriers to successful allogeneic hematopoietic stem cell transplantation; these include host-versus-graft reactions, graft failure, acute and chronic graft-versus-host disease (GVHD), regimen-related toxicities, and induction of graft-versus-tumor reactions.
Overview of Rainer Storb's Research Focus
His overall research focus is cancer immunology and clinical expertise is treating patients with blood cancers.
Rainer Storb - Brief Curriculum Vitae
Appointments, affiliations and researcher interests
Research combines basic and translational research directed at understanding and eliminating major barriers to successful allogeneic hematopoietic stem cell transplantation.
Clinical Research Division
Researchers conduct laboratory and patient-oriented research to better understand the mechanisms that drive cancer and other human diseases. Integrating a variety of disciplines, our investigators are continually developing new therapeutic approaches and leading clinical trials that help move discoveries from laboratory to patient. Our pioneering research has saved hundreds of thousands of lives.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.